Navigation Links
Gene Therapy Shows Potential Against Heart Failure
Date:11/16/2010

By Amanda Gardner
HealthDay Reporter

TUESDAY, Nov. 16 (HealthDay News) -- By substituting a healthy gene for a defective one, scientists were able to partially restore the heart's ability to pump in 39 heart failure patients, researchers report.

"This is the first time gene therapy has been tested and shown to improve outcomes for patients with advanced heart failure," study lead author Dr. Donna Mancini, professor of medicine and the Sudhir Choudhrie professor of cardiology at Columbia University College of Physicians and Surgeons in New York City, said in a university news release.

"The therapy works by replenishing levels of an enzyme necessary for the heart to pump more efficiently by introducing the gene for SERCA2a, which is depressed in these patients. If these results are confirmed in future trials, this approach could be an alternative to heart transplant for patients without any other options," she added.

Mancini presented the results Monday at the annual meeting of the American Heart Association (AHA) in Chicago.

The gene for SERCA2a raises levels of the enzyme back to where the heart can pump more efficiently. The enzyme regulates calcium cycling, which, in turn, is involved in how well the heart contracts, the researchers said.

"Heart failure is a defect in contractility related to calcium cycling," explained Dr. Robert Eckel, past president of the AHA and professor of medicine at the University of Colorado Denver.

The study authors hope that, if replicated in larger trials, the gene-therapy treatment could actually delay or obviate the need for heart transplants in patients with heart failure.

"There are a lot of treatments for heart failure but at some point patients stop responding and then the prognosis is poor," said Dr. Rita Redberg, AHA spokeswoman and professor of medicine at the University of California, San Francisco. After that, the only option is a transplant.

For this phase 2 study, 39 patients with advanced heart failure were randomly chosen to receive either the gene therapy (through cardiac catheterization) or a placebo.

At both six months and a year later, the patients who had received the new gene saw their risk for death, cardiac transplantation, worsening heart failure and hospitalization decline by half.

Results were even more heartening at higher doses, where participants had an 88 percent decrease in risk for death, cardiac transplant, hospitalizations and other outcomes, the study authors said.

Redberg cautioned that the study was still preliminary and "requires more investigation."

And research presented at meetings isn't subjected to the same level of scrutiny as studies published in peer-reviewed journals.

The study was funded by the Celladon Corp. of La Jolla, Calif.

More information

The American Heart Association has more on heart failure.

SOURCES: Rita Redberg, M.D., professor of medicine, University of California, San Francisco, and spokeswoman, American Heart Association; Robert Eckel, M.D., professor of medicine, University of Colorado Denver, and past president, American Heart Association; study abstract, Nov. 14, 2010, American Heart Association annual meeting, Chicago


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Nicotine replacement therapy is over-promoted since most ex-smokers quit unassisted
2. Social Anxiety and Panic - Alternative Treatment to Drugs and Therapy
3. Longview Therapy Center, PLLC, Unveils Its Definition Of Hope
4. Short-term radiation therapy successful on breast cancer
5. ASCROs Response to NY Times Articles on Radiation Therapy Incidents
6. Children With Cerebral Palsy Benefitting From New Physical Therapy Regimen
7. DavisPTnetwork Partners with the New York Physical Therapy Association to Provide Online Continuing Education
8. Behavioral therapy improves sleep and lives of patients with pain
9. WHI data confirm short-term heart disease risks of combination menopausal hormone therapy
10. Promising therapy for relapsing multibple sclerosis
11. Split-course palliative radiotherapy confirmed as effective treatment for advanced NSCLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... Newport Beach, CA (PRWEB) , ... December 04, ... ... youthful appearance without undergoing major cosmetic surgery can now take advantage of a ... is an advanced skin rejuvenation treatment that reduces the appearance of age spots, ...
(Date:12/4/2016)... ... December 04, 2016 , ... Responsible dental care hinges on regular ... to achieve optimal results. This important necessity inspired an inventor from Las Vegas, Nev., ... to ensure that people break or avoid bad techniques of brushing the teeth in ...
(Date:12/2/2016)... ... December 02, 2016 , ... Lori G. Cohen and ... office, will speak at the American Conference Institute’s 21st Drug & Medical Device ... a Lead Sponsor of the conference. , Cohen, who chairs the firm’s Pharmaceutical, Medical ...
(Date:12/2/2016)... Calif. (PRWEB) , ... December 02, 2016 , ... On ... at the Hard Rock Hotel San Diego honoring the 2016 MPN Heroes—eight individuals who ... neoplasms (MPNs) by going above and beyond the standard of care, demonstrating leadership within ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... Area in Alabama are expected to attend the UNCF Dothan-Wiregrass Mayor’s Luncheon Dec. ... scholarship funds for area students and operating support to UNCF-member institutions, including Miles ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... , December 2, 2016 Orthopedic ... & Support) is Expected to Gain a Significant Market Share ... Orthopedic Ailments  ... , According to a ... on Medical Implants Sterile Packaging: Clamshell Product Type Segment Projected ...
(Date:12/2/2016)... N.J. , Dec. 2, 2016   CytoSorbents ... immunotherapy leader commercializing its European Union approved CytoSorb ... and cardiac surgery patients worldwide, announced that Dr. ... the 9th Annual LD Micro Main Event ... , 2016 at the Luxe Sunset Boulevard Hotel in ...
(Date:12/2/2016)... , December 2, 2016 On Thursday, ... 1.36%; the Dow Jones Industrial Average edged 0.36% higher, to ... down 0.35%. Losses were broad based as six out of ... initiated research reports on the following Services equities: Myriad Genetics ... QGEN ), INC Research Holdings Inc. (NASDAQ: ...
Breaking Medicine Technology: